Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 5/20 | 0.32 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | CA9 | Q16790 | 5/20 | 0.32 |
| ▸ | CA4 | P22748 | 4/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28979458 | 0.83 | CA2 (0.35) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL3460148 | 0.79 | KDM4E (0.35) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL3521419 | 0.79 | CHRNB2 (0.36) | ATMCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL7817864 | 0.78 | KDM4E (0.38) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL954895 | 0.78 | DPP4 (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL18983307 | 0.78 | KDM4E (0.34) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL954793 | 0.78 | DPP4 (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL954795 | 0.78 | DPP4 (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL572568 | 0.78 | KDM4E (0.38) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Water SCHEMBL7151392 | 0.76 | KDM4E (0.37) | KDM4EMAPTKMT2AATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329644-B2 | Lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-12-11 | — | — | US | claimed |
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-10-14 | — | — | US | claimed |
| EP-2167527-A2 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | Novacta Biosystems Limited (GB) | 2010-03-31 | — | — | EP | claimed |
| WO-2009010765-A2 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-01-22 | — | — | WO | claimed |
| WO-2014016613-A2 | THE USE OF TYPE-B LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB/GB) (GB) | 2014-01-30 | — | — | WO | disclosed |
| US-8575094-B2 | Use of type-B lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-8329644-B2 | Lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8183202-B2 | — | — | 2012-05-22 | — | — | US | disclosed |
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| EP-2178552-A1 | THE USE OF TYPE-B LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | Novacta Biosystems Limited (GB) | 2010-04-28 | — | — | EP | disclosed |
| EP-2167527-A2 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | Novacta Biosystems Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009010763-A1 | THE USE OF TYPE-B LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010765-A2 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | GPR6, GALR3, NTSR1 | KDM4E 4347/4885MAPT 4853/4885KMT2A 4436/4885 |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | MTPN, NISCH, VIP | KDM4E 4789/4885MAPT 2391/4885KMT2A 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.